CLASS III Drug recall · Reported 27 Apr 2016 · FDA Enforcement Report
Zemplar (paricalcitol) capsules, 1 mcg recalled by AbbVie
AbbVie is recalling Zemplar (paricalcitol) capsules, 1 mcg, distributed nationwide in the US. The recall was initiated on 24 Mar 2016 and the FDA has classified it as Class III.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0833-2016
- FDA event ID
- 73611
- Recalling firm
- AbbVie, North Chicago, IL
- Brand
- Zemplar
- Manufacturer
- AbbVie Inc.
- Classification
- Class III
- Status
- Terminated
- Recall initiated
- 24 Mar 2016
- FDA classified
- 21 Apr 2016
- Reported
- 27 Apr 2016
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Other Reasons
- Drug class
- Vitamins & OTC Supplements
Timeline
| 24 Mar 2016 | Recall initiated by company | |
| 21 Apr 2016 | Classified by FDA | +28 days |
| 27 Apr 2016 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Failed Content Uniformity Specifications
Product as listed by the FDA
Zemplar (paricalcitol) capsules, 1 mcg, 30-count bottle, Rx Only, Mfd for AbbVie Inc. North Chicago, IL 60064, NDC 0074-4317-30.
Where it was distributed
Nationwide
Questions about this recall
Why was it recalled?
Failed Content Uniformity Specifications
Which lots are affected?
Lot #1055586, Exp.1/21/ 2018
Where was it sold?
Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class III mean?
Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from AbbVie
All 20| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Pred Mild, prednisolone acetate ophthalmic suspension recalled by AbbViePred Mild | AbbVie | Potency & Assay | Nationwide |
| Drug | CLASS II | Refresh Lacri-lube, (42.5% Mineral Oil recalled by AbbVie | AbbVie | Sterility | Nationwide |
| Drug | CLASS II | Refresh P.M., (Mineral Oil recalled by AbbVie | AbbVie | Sterility | Nationwide |
| Drug | CLASS III | Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg) recalledSynthroid | AbbVie | Other | IL |
| Drug | CLASS III | Ultane (sevoflurane), Inhalation Anesthetic recalled by AbbVieUltane | AbbVie | Packaging Defects | MS, OH |
Other Paricalcitol recalls
All 11| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Paricalcitol Capsules, 1 mcg recalled by Teva Pharmaceuticals U | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS III | Paricalcitol Capsules, 4 mcg recalled by Teva Pharmaceuticals U | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS III | Paricalcitol Capsules, 2 mcg recalled by Teva Pharmaceuticals U | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS III | Paricalcitol Capsules, 1 mcg recalled by Amerisource Health Services | Amerisource Health Services | Potency & Assay | Nationwide |
| Drug | CLASS II | Paricalcitol Capsules, 1 mcg recalled by Teva Pharmaceuticals U | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |